II. Epidemiology
-
Incidence
- Children in UK: 11 to 95 per 100,000 person years (UK data)
- Children in US: 40 to 78 per 100,000 (hospitalization rate)
- Age
- More common in children (immature Immune Systems)
- References
III. Pathophysiology
- Severe, disseminated Skin Infection with Herpes Simplex Virus (typically type 1)
- Infections are typically in patients with skin barrier defects (esp. Atopic Dermatitis, see risk factors below)
- Contributing factors
- Dysregulated immune response
- Altered skin flora
- Environmental exposures
IV. Risk Factors
- Younger children
- Atopic Dermatitis (esp. early onset, and under-treated)
- Seborrheic Dermatitis
- Burn Injury
- Post-operative complication (e.g. Cosmetic dermatology procedure)
- Inflammatory skin conditions
V. Symptoms
- Painful papulovesicular rash spread over localized skin region
VI. Signs
- Characteristics
- Distribution
- May affect any region with Atopic Dermatitis
- Head
- Face
- Neck
- Chest
- Severity
- Atopic Dermatitis severity correlates with Eczema Herpeticum severity
- Children are prone to more severe cases
- Associated findings
- Fever
- Malaise
- Lymphadenopathy
- Other systemic herpetic complications
- Herpes Simplex Keratitis (Keratoconjunctivitis)
- Corneal exam should include Fluorescein staining if periorbital infection is present
- Herpes Gingivostomatitis (may limit oral intake)
- HSV Encephalitis (Meningoencephalitis)
- Herpetic Whitlow
- Herpes Simplex Keratitis (Keratoconjunctivitis)
VII. Labs
-
HSV PCR
- Do NOT delay treatment while awaiting results
- Other laboratory testing as indicated (e.g. septic workup with Blood Cultures)
- Basic chemistry panel including Renal Function (baseline and as needed, esp. with Acyclovir IV)
- Consider MRSA swabs (if superinfection suspected)
VIII. Differential Diagnosis
IX. Complications
- Skin superinfections (e.g. MSSA or MRSA, Streptococcus Pyogenes)
- Herpes Simplex Keratitis
- Herpes Gingivostomatitis
- Systemic disease
- Viremia
- Bacteremia
- Death
- Mortality 0.1% with Antiviral management
X. Management
- Dermatologic emergency requiring prompt initiation of Antiviral therapy
- Consult dermatology
- Hospitalization
- Indications
- Management often starts with IV Antivirals (esp. children)
- Severe presentations
- Extensive disease involving the face, eye or Central Nervous System
- Management
- IV Acyclovir (and follow Renal Function)
- Transition to oral agents when able (see below)
- Treat superinfections (e.g. MSSA, MRSA)
- Intravenous Fluids as needed
- IV Acyclovir (and follow Renal Function)
- Indications
- Outpatient Management
- Antivirals
- Acyclovir 20 mg/kg/dose (up to 800 mg) orally 5 times daily
- Valacyclovir 20 mg/kg/dose (up to 1000 mg) orally twice daily
- Treat superinfections (e.g. MSSA, MRSA) if present
- Cephalexin 50 mg/kg/day divided three times daily for 7 days
- Consider MRSA coverage
- Antivirals
- Symptomatic management
- See Atopic Dermatitis for general measures
- Skin Emollients (e.g. petroleum jelly)
- Topical antibacterial as needed (e.g. Mupirocin)
- Medium potency Topical Corticosteroids may be considered (e.g. Triamcinolone cream)
- Topical Corticosteroids are safe in Eczema Herpeticum without worsening outcomes
XI. Course
- Lesions resolve with treatment over 2 to 6 weeks
XII. References
- Farnsworth (2026) Crit Dec Emerg Med 40(7): 17-8
- Laporte (2025) Crit Dec Emerg Med 39(12): 16-7